Synonyms
Status
Molecule Category Mixture
ATC N06AF04
UNII 3E3V44J4Z9

Structure

InChI Key IGLYMJRIWWIQQE-QUOODJBBSA-N
Smiles N[C@@H]1C[C@H]1c1ccccc1.N[C@H]1C[C@@H]1c1ccccc1
InChI
InChI=1S/2C9H11N/c2*10-9-6-8(9)7-4-2-1-3-5-7/h2*1-5,8-9H,6,10H2/t2*8-,9+/m10/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C18H22N2
Molecular Weight 266.39
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None
Assay Description Organism Bioactivity Reference
Inhibition of MAO in rat brain homogenate at 5 uM using kynuramine as substrate by fluorimetry Rattus norvegicus 91.56 %
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting Homo sapiens -9.5 %
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting Homo sapiens -9.3 %
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting Homo sapiens 15.5 %
Inhibition of human recombinant MAO-B assessed as kynuramine oxidation to 4-hydroxyquinoline after 40 mins by LC-MS/MS analysis Homo sapiens 250.0 nM
Inhibition of human recombinant MAO-A assessed as kynuramine oxidation to 4-hydroxyquinoline after 40 mins by LC-MS/MS analysis Homo sapiens 240.0 nM
Inhibition of LSD1 (unknown origin) at 10 uM relative to control Homo sapiens 18.4 %
Inhibition of human recombinant soluble MAO-B expressed in Pichia pastoris incubated for 30 mins prior to substrate addition measured after 60 mins by MAO-Glo assay Homo sapiens 26.0 nM
Inhibition of human recombinant LSD1 at 10 uM after 30 mins to 4 hrs by fluorescence assay relative to control Homo sapiens 18.0 %
Inhibition of human recombinant MAOB expressed in Pichia pastoris incubated for 15 mins prior to substrate addition measured after 30 mins by luminescence assay Homo sapiens 890.0 nM
Inhibitory activity of 100 uM tranylcypromine on 1.2 Pmoles of cDNA-derived CYP2A6 enzyme in microsome prepared from human lymphoblastoid cell line Homo sapiens 97.0 %
Inhibitory activity of 100 uM tranylcypromine on 0.6 Pmoles of cDNA-derived CYP2A6 enzyme in microsome prepared from human lymphoblastoid cell line Homo sapiens 98.0 %
Inhibitory activity of 100 uM tranylcypromine on 0.3 Pmoles of cDNA-derived CYP2A6 enzyme in microsome prepared from human lymphoblastoid cell line Homo sapiens 99.0 %
Inhibitory activity of 100 uM tranylcypromine on 49 Pmoles of cDNA-derived CYP2C19 enzyme in microsome prepared from human lymphoblastoid cell line Homo sapiens 96.0 %
Inhibitory activity of 100 uM tranylcypromine on 15 Pmoles of cDNA-derived CYP2C19 enzyme in microsome prepared from human lymphoblastoid cell line Homo sapiens 99.0 %
Inhibitory activity of 100 uM tranylcypromine on 34 Pmoles of cDNA-derived CYP2C19 enzyme in microsome prepared from human lymphoblastoid cell line Homo sapiens 97.0 %
Mixed inhibition of CYP2A6 (unknown origin) Homo sapiens 130.0 nM
Inhibition Assay: The inhibition of human CYP2A6-mediated 7-hydroxy coumarin formation was evaluated in the presence of 95 selected test compounds in a standard assay (Greenlee et al., J Pharmacol Exp Ther, 1978). Our first studies were with highly purified human CYP2A6 that provided a convenient and relatively high-throughput measure of CYP2A6 inhibition. Homo sapiens 970.0 nM Inhibition Assay: The inhibition of human CYP2A6-mediated 7-hydroxy coumarin formation was evaluated in the presence of 95 selected test compounds in a standard assay (Greenlee et al., J Pharmacol Exp Ther, 1978). Our first studies were with highly purified human CYP2A6 that provided a convenient and relatively high-throughput measure of CYP2A6 inhibition. Homo sapiens 80.0 nM Inhibition Assay: The inhibition of human CYP2A6-mediated 7-hydroxy coumarin formation was evaluated in the presence of 95 selected test compounds in a standard assay (Greenlee et al., J Pharmacol Exp Ther, 1978). Our first studies were with highly purified human CYP2A6 that provided a convenient and relatively high-throughput measure of CYP2A6 inhibition. Homo sapiens 970.0 nM
Inhibition of recombinant human MAOB incubated for 15 mins measured after 30 mins by luminescence-Glo assay Homo sapiens 800.0 nM

Cross References

Resources Reference
ChEMBL CHEMBL3989843
FDA SRS 3E3V44J4Z9
Guide to Pharmacology 5281
PubChem 19493